September 16, 2019Open Access

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

Key Points

Key points are not available for this paper at this time.

Abstract

We demonstrate that after 3 yr of prostate-specific antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than in those without these mutations. We recommend that male BRCA2 carriers are offered systematic PSA screening.

Bookmark

View Full Paper

Cite This Study

Page et al. (Mon,) studied this question.

synapsesocial.com/papers/69df0c73b8d7e9456661432b https://doi.org/https://doi.org/10.1016/j.eururo.2019.08.019

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.20172016 · 661 citations
2Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up2014 · 1,566 citations
3INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer2016 · 48 citations
4Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up2016 · 217 citations
5Mortality results from the Göteborg randomised population-based prostate-cancer screening trial2010 · 936 citations

Bookmark

View Full Paper